Hypermarcas (OTCMKTS:HYPMY) Shares Gap Down – Time to Sell?

Hypermarcas (OTCMKTS:HYPMY) gapped down prior to trading on Wednesday. The stock had previously closed at $5.3590, but opened at $5.10. Hypermarcas shares last traded at $5.40, with a volume of 333 shares changing hands.

Analysts Set New Price Targets

Separately, Jefferies Financial Group upgraded shares of Hypermarcas to a “strong-buy” rating in a research note on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy”.

Hypermarcas Stock Performance

The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.26 and a current ratio of 1.86. The stock has a 50 day moving average of $4.61 and a 200 day moving average of $4.42. The stock has a market capitalization of $3.80 billion, a P/E ratio of 10.80 and a beta of 0.65.

Hypermarcas (OTCMKTS:HYPMY) last posted its earnings results on Thursday, August 6th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.01. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. Equities analysts predict that Hypermarcas will post 0.51 EPS for the current year.

Hypermarcas Company Profile

Hypermarcas SA was a Brazilian consumer-health and pharmaceutical company that later changed its corporate name to Hypera SA The company was established as a diversified consumer-products business and, over time, shifted its focus toward pharmaceuticals and healthcare products.

Hypera develops, manufactures and markets prescription medicines, generic and branded-generic drugs, over-the-counter products, vitamins and nutritional supplements. Its portfolio has included well-known Brazilian consumer-health brands such as Neosaldina, Doril, Engov, Benegrip and Addera D3, serving categories including pain relief, cold and flu treatment, digestive health and vitamins.

The company’s principal market is Brazil, where its products are distributed through pharmacies, retailers and other healthcare channels.